Novel Tissues Profile
Key Indicators
- Authorised Capital ₹ 2.40 M
as on 16-11-2024
- Paid Up Capital ₹ 2.40 M
as on 16-11-2024
- Company Age 21 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 22.10 Cr
as on 16-11-2024
- Revenue 31.91%
(FY 2023)
- Profit 28.21%
(FY 2023)
- Ebitda 44.51%
(FY 2023)
- Net Worth 31.22%
(FY 2023)
- Total Assets 47.40%
(FY 2023)
About Novel Tissues
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.40 M and a paid-up capital of Rs 2.40 M.
The company currently has active open charges totaling ₹22.10 Cr.
Adaviappa Doddamani and Lava Doddamani serve as directors at the Company.
- CIN/LLPIN
U05190KA2003PTC032338
- Company No.
032338
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jul 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Mysore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Novel Tissues Private Limited offer?
Novel Tissues Private Limited offers a wide range of products and services, including Salon, Spa Kits & Equipments, Salon Consumables & Disposables, Hand Sanitizers & Personal Hygiene, Air Fresheners, Medical & Surgical Clothing, Medical Pads, Wet Wipes, Child and Baby Care Products, Baby Care Products, Cleaning Liquids & Wipes.
Who are the key members and board of directors at Novel Tissues?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Adaviappa Doddamani  | Director | 08-Sep-2011 | Current |
| Lava Doddamani | Director | 11-Nov-2013 | Current |
Financial Performance of Novel Tissues.
Novel Tissues Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.91% increase. The company also saw a substantial improvement in profitability, with a 28.21% increase in profit. The company's net worth Soared by an impressive increase of 31.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novel Tissues?
In 2023, Novel Tissues had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 21 Mar 2023 | ₹6.00 M | Open |
Sidbi Creation Date: 16 Jun 2022 | ₹6.95 Cr | Open |
Sidbi Creation Date: 29 Mar 2022 | ₹6.35 Cr | Open |
How Many Employees Work at Novel Tissues?
Novel Tissues has a workforce of 3 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novel Tissues, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novel Tissues's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
